Johnson & Johnson Stock

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 16:00:02 2024-04-12 EDT 5-day change 1st Jan Change
147.5 USD -0.85% Intraday chart for Johnson & Johnson -3.20% -5.88%
Sales 2024 * 88.42B 122B Sales 2025 * 90.88B 125B Capitalization 355B 490B
Net income 2024 * 21.22B 29.22B Net income 2025 * 22.29B 30.7B EV / Sales 2024 * 3.89 x
Net cash position 2024 * 11.34B 15.62B Net cash position 2025 * 24.89B 34.28B EV / Sales 2025 * 3.64 x
P/E ratio 2024 *
16.8 x
P/E ratio 2025 *
15.9 x
Employees 131,900
Yield 2024 *
3.33%
Yield 2025 *
3.48%
Free-Float 77.1%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.85%
1 week-3.20%
Current month-6.75%
1 month-9.35%
3 months-9.16%
6 months-5.64%
Current year-5.88%
More quotes
1 week
147.15
Extreme 147.15
153.04
1 month
147.15
Extreme 147.15
161.54
Current year
147.15
Extreme 147.15
163.58
1 year
144.95
Extreme 144.95
175.97
3 years
144.95
Extreme 144.95
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Chief Tech/Sci/R&D Officer 58 19-11-04
Members of the board TitleAgeSince
Director/Board Member 70 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-04-12 147.5 -0.85% 7,100,178
24-04-11 148.8 -0.94% 8,374,434
24-04-10 150.2 -1.37% 6,809,519
24-04-09 152.3 +0.46% 6,135,556
24-04-08 151.6 -0.52% 5,935,415

Delayed Quote Nyse, April 12, 2024 at 04:00 pm

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
147.5 USD
Average target price
175.4 USD
Spread / Average Target
+18.87%
Consensus